CERE — Cerevel Therapeutics Holdings Share Price
0.000.00%
Last trade - 00:00- $8.19bn
- $7.68bn
- 36
- 15
- 91
- 44
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 13.44 | ||
| Price to Tang. Book | 13.44 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -47% | ||
| Return on Equity | -92.45% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Cerevel Therapeutics Holdings, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on neuroscience that combines an understanding of disease-related biology and neurocircuitry of the brain with advanced chemistry and central nervous system (CNS) target receptor selective pharmacology to discover and design new therapies. It focuses on transform the lives of patients through the development of new therapies for neuroscience diseases, including schizophrenia, Alzheimer’s disease psychosis, epilepsy, panic disorder and Parkinson’s disease. Its pipeline candidates include Emraclidine, Darigabat, Tavapadon and CVL-871. Emraclidine is a positive allosteric modulator (PAM), that selectively targets the muscarinic acetylcholine 4 receptor subtype (M4). Darigabat is a PAM that selectively targets the alpha 2/3/5 subunits of the GABAA receptor. Tavapadon is a selective dopamine D1/D5 receptor partial agonist that it is developing for the treatment of Parkinson’s disease.
Directors
- N. Anthony Coles CHM (61)
- Mark Bodenrader CFO (48)
- Kenneth DiPietro CHO (62)
- John Renger CSO (52)
- Raymond Sanchez OTH (60)
- Kathleen Tregoning OTH (50)
- Deborah Baron IND (52)
- Morris Birnbaum IND (69)
- Marijn Dekkers IND (63)
- Douglas Giordano IND (58)
- Chris Gordon IND (46)
- Adam Koppel IND (51)
- Ruth Mckernan IND (63)
- Deval Patrick IND (64)
- Norbert Riedel IND (63)
- Gabrielle Sulzberger IND (61)
- Last Annual
- December 31st, 2023
- Last Interim
- March 31st, 2024
- Incorporated
- October 27th, 2020
- Public Since
- June 5th, 2020
- No. of Shareholders
- 3
- No. of Employees
- 355
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 182,194,722
- Address
- 222 Jacobs Street, Suite 200, CAMBRIDGE, 02141
- Web
- https://www.cerevel.com/
- Phone
- +1 2122842300
- Auditors
- Ernst & Young LLP
Upcoming Events for CERE
Q3 2024 Cerevel Therapeutics Holdings Inc Earnings Release
Similar to CERE
180 Life Sciences
NASDAQ Capital Market
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
FAQ
What is the Cerevel Therapeutics Holdings share price?
As of Today at 13:21 UTC, shares in Cerevel Therapeutics Holdings are trading at $41.65. This share price information is delayed by 15 minutes.
How has the Cerevel Therapeutics Holdings share price performed this year?
Shares in Cerevel Therapeutics Holdings last closed at $41.65 and the price had moved by +24.74% over the past 365 days. In terms of relative price strength the Cerevel Therapeutics Holdings share price has underperformed the S&P500 Index by -0.74% over the past year.
What are the analyst and broker recommendations for Cerevel Therapeutics Holdings?
The overall consensus recommendation for Cerevel Therapeutics Holdings is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Cerevel Therapeutics Holdings dividend yield?
Cerevel Therapeutics Holdings does not currently pay a dividend.
Does Cerevel Therapeutics Holdings pay a dividend?
Cerevel Therapeutics Holdings does not currently pay a dividend.
When does Cerevel Therapeutics Holdings next pay dividends?
Cerevel Therapeutics Holdings does not currently pay a dividend.
How do I buy Cerevel Therapeutics Holdings shares?
To buy shares in Cerevel Therapeutics Holdings you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Cerevel Therapeutics Holdings?
As of the previous close price of $41.65, shares in Cerevel Therapeutics Holdings had a market capitalisation of $7.59bn.
Where are Cerevel Therapeutics Holdings shares listed?
Here are the trading details for Cerevel Therapeutics Holdings:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: CERE
What kind of share is Cerevel Therapeutics Holdings?
Based on an overall assessment of its quality, value and momentum Cerevel Therapeutics Holdings is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Cerevel Therapeutics Holdings share price forecast for 2024?
The analyst consensus target price for shares in Cerevel Therapeutics Holdings is $43.40. That is 4.2% above the last closing price of $41.65.
Analysts covering Cerevel Therapeutics Holdings currently have a consensus Earnings Per Share (EPS) forecast of -$2.52 for the next financial year.
Find out moreWhat is the trend in the Cerevel Therapeutics Holdings share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Cerevel Therapeutics Holdings. Over the past six months, its share price has underperformed the S&P500 Index by -13.15%.
As of the last closing price of $41.65, shares in Cerevel Therapeutics Holdings were trading +15.81% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Cerevel Therapeutics Holdings PE Ratio?
The Cerevel Therapeutics Holdings PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $41.65.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Cerevel Therapeutics Holdings?
Cerevel Therapeutics Holdings' management team is headed by:
- N. Anthony Coles - CHM
- Mark Bodenrader - CFO
- Kenneth DiPietro - CHO
- John Renger - CSO
- Raymond Sanchez - OTH
- Kathleen Tregoning - OTH
- Deborah Baron - IND
- Morris Birnbaum - IND
- Marijn Dekkers - IND
- Douglas Giordano - IND
- Chris Gordon - IND
- Adam Koppel - IND
- Ruth Mckernan - IND
- Deval Patrick - IND
- Norbert Riedel - IND
- Gabrielle Sulzberger - IND